Hilsenbeck SG - Search Results

1

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.

Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC. Rimawi MF, et al. Among authors: hilsenbeck sg. J Clin Oncol. 2013 May 10;31(14):1726-31. doi: 10.1200/JCO.2012.44.8027. Epub 2013 Apr 8. J Clin Oncol. 2013. PMID: 23569315 Free PMC article. Clinical Trial.

2

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Osborne CK, et al. Among authors: hilsenbeck sg. J Natl Cancer Inst. 1995 May 17;87(10):746-50. doi: 10.1093/jnci/87.10.746. J Natl Cancer Inst. 1995. PMID: 7563152

3

Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.

Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Reddy KB, et al. Among authors: hilsenbeck sg. Cell Growth Differ. 1994 Dec;5(12):1275-82. Cell Growth Differ. 1994. PMID: 7696176

4

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. Osborne CK, et al. Among authors: hilsenbeck sg. Cancer Chemother Pharmacol. 1994;34(2):89-95. doi: 10.1007/BF00685924. Cancer Chemother Pharmacol. 1994. PMID: 8194171

5

The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines.

Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. Oesterreich S, et al. Among authors: hilsenbeck sg. Cancer Res. 1993 Oct 1;53(19):4443-8. Cancer Res. 1993. PMID: 8402609

6

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD. Rothenberg ML, et al. Among authors: hilsenbeck sg. J Clin Oncol. 1996 Apr;14(4):1128-35. doi: 10.1200/JCO.1996.14.4.1128. J Clin Oncol. 1996. PMID: 8648367 Clinical Trial.

7

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.

Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N. Grøndahl-Hansen J, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1997 Apr;43(2):153-63. doi: 10.1023/a:1005744914124. Breast Cancer Res Treat. 1997. PMID: 9131271

8

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: hilsenbeck sg. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

9

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.

Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM. Diab SG, et al. Among authors: hilsenbeck sg. J Clin Oncol. 1998 May;16(5):1655-60. doi: 10.1200/JCO.1998.16.5.1655. J Clin Oncol. 1998. PMID: 9586875

10

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Brown RW, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1996 Mar;2(3):585-92. Clin Cancer Res. 1996. PMID: 9816207

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

366 results

Search Page